Key papers in Ophthalmology

Pofolia’s corpus holds 49 papers from the Ophthalmology subfield (2012–2021). The list below starts with the most cited.

Most cited

Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.

  • Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

    The Lancet Global Health · 2014 · Q1 · SJR 5.00 · FWCI 35.91 · 5,326 citations

    This meta-analysis estimates that 8.69% of individuals aged 45-85 have age-related macular degeneration (AMD), with projections indicating the number of affected people will rise from 196 million in 2020 to 288 million by 2040.

    Go to source

  • Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy

    Cellular Physiology and Biochemistry · 2017 · Q3 · FWCI 363.11 · 5,140 citations · Open access

    Anti-VEGF drugs Aflibercept and Ranibizumab protect retinal pigment epithelium (RPE) cells from oxidative damage by increasing nitric oxide (NO) release and modulating autophagy pathways.

    Go to source

  • Global Prevalence and Major Risk Factors of Diabetic Retinopathy

    Diabetes Care · 2012 · Q1 · SJR 7.00 · FWCI 115.75 · 4,940 citations · Open access

    Diabetic retinopathy (DR) affects 34.6% of people with diabetes globally, with 10.2% experiencing vision-threatening DR (VTDR). These conditions are significantly linked to longer diabetes duration and poorer glycemic and blood pressure control.

    Go to source

  • The Pathophysiology and Treatment of Glaucoma

    JAMA · 2014 · Q1 · SJR 5.00 · FWCI 90.11 · 4,103 citations

    Glaucoma, a leading cause of irreversible vision loss, is characterized by progressive optic nerve damage, often linked to intraocular pressure. Reducing intraocular pressure is the only proven treatment method.

    Go to source

  • Indian Journal Of Science And Technology

    Indian Journal of Science and Technology · 2019 · FWCI 130.40 · 1,914 citations

    The Indian Journal of Science and Technology is an open-access journal that publishes full-length research papers and review articles.

    Go to source

  • Optical coherence tomography angiography

    Progress in Retinal and Eye Research · 2017 · Q1 · SJR 5.00 · FWCI 84.02 · 1,740 citations · Open access

    Optical coherence tomography angiography (OCTA) is a decade-old imaging technology that provides unprecedented, depth-resolved visualization of retinal and choroidal blood flow, surpassing older methods.

    Go to source

  • Retinal Vascular Layers Imaged by Fluorescein Angiography and Optical Coherence Tomography Angiography

    JAMA Ophthalmology · 2014 · Q1 · SJR 2.00 · FWCI 111.68 · 1,615 citations

    Optical coherence tomography (OCT) angiography successfully visualized the radial peripapillary capillary network, a feat not achieved by conventional fluorescein angiography in 12 healthy eyes.

    Go to source

  • Diabetic Retinopathy

    New England Journal of Medicine · 2012 · Q1 · SJR 18.00 · FWCI 63.94 · 1,600 citations

    Despite rising diabetes rates, diabetic retinopathy incidence is declining, likely due to improved management of glucose, lipids, and blood pressure.

    Go to source

  • Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

    New England Journal of Medicine · 2015 · Q1 · SJR 18.00 · FWCI 150.72 · 1,586 citations · Open access

    Intravitreous aflibercept, bevacizumab, and ranibizumab all improved vision in patients with diabetic macular edema, but aflibercept showed greater efficacy only in eyes with worse baseline visual acuity.

    Go to source

  • Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss

    Eye and Vision · 2015 · Q1 · SJR 1.00 · FWCI 60.23 · 1,580 citations · Open access

    Diabetic retinopathy (DR) affects about one-third of the estimated 285 million people with diabetes globally, with a third of those cases being vision-threatening, including diabetic macular edema (DME).

    Go to source

  • The Lancet Global Health Commission on Global Eye Health: vision beyond 2020

    The Lancet Global Health · 2021 · Q1 · SJR 5.00 · FWCI 171.45 · 1,543 citations · Open access

    Improving global eye health is a cost-effective strategy that unlocks human potential and directly contributes to achieving multiple Sustainable Development Goals, including poverty reduction, improved productivity, and better general health.

    Go to source

  • The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria

    Journal of the European Academy of Dermatology and Venereology · 2013 · Q1 · SJR 2.00 · FWCI 45.56 · 1,462 citations

    New International Criteria for Behçet's Disease (ICBD) demonstrate significantly improved sensitivity (94.8%) compared to existing criteria (85.0%), while maintaining reasonable specificity (90.5%). These criteria were developed using data from 2556 patients and 1163 controls across 27 countries.

    Go to source

  • The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age‐Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults

    Oxidative Medicine and Cellular Longevity · 2016 · Q1 · SJR 1.00 · FWCI 88.19 · 1,452 citations · Open access

    Reactive oxygen species (ROS) are implicated in the pathogenesis of numerous adult eye diseases, including corneal dystrophies, glaucoma, optic neuropathies, cataracts, and age-related macular degeneration.

    Go to source

  • Diabetic Retinopathy: Pathophysiology and Treatments

    International Journal of Molecular Sciences · 2018 · Q1 · SJR 1.00 · FWCI 62.61 · 1,363 citations · Open access

    Diabetic retinopathy (DR), a common diabetes complication, involves more than just microvascular damage, with inflammation and neurodegeneration also contributing significantly to retinal damage.

    Go to source

  • Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China

    JAMA Ophthalmology · 2020 · Q1 · SJR 2.00 · FWCI 185.86 · 1,284 citations · Open access

    Approximately one-third (31.6%) of COVID-19 patients exhibited ocular manifestations like conjunctivitis, and a small percentage (5.2%) showed SARS-CoV-2 presence in conjunctival swabs.

    Go to source

  • Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection

    Journal of Medical Virology · 2020 · Q1 · SJR 1.00 · FWCI 171.00 · 1,149 citations

    SARS-CoV-2 RNA was detected in tear and conjunctival secretions from one out of 30 patients with COVID-19, specifically in the single patient who presented with conjunctivitis.

    Go to source

  • A review of optical coherence tomography angiography (OCTA)

    International Journal of Retina and Vitreous · 2015 · Q1 · SJR 1.00 · FWCI 68.34 · 1,132 citations · Open access

    Optical coherence tomography angiography (OCTA) is a novel, non-invasive imaging technique that rapidly produces volumetric angiographic images, offering detailed structural and blood flow information for retinal vascular diseases.

    Go to source

  • Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

    Ophthalmology · 2014 · Q1 · SJR 3.00 · FWCI 82.36 · 1,117 citations

    A three-year trial found that dexamethasone intravitreal implants (Ozurdex) at both 0.7 mg and 0.35 mg doses significantly improved visual acuity and reduced retinal thickness in patients with diabetic macular edema compared to sham treatment.

    Go to source

  • Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review

    Clinical and Experimental Ophthalmology · 2015 · Q1 · SJR 1.00 · FWCI 26.74 · 1,074 citations · Open access

    Diabetic retinopathy (DR) is a major global cause of vision loss, with rising diabetes incidence posing significant public health and cost challenges for screening programs.

    Go to source

  • Diabetic retinopathy: current understanding, mechanisms, and treatment strategies

    JCI Insight · 2017 · Q1 · SJR 2.00 · FWCI 57.27 · 1,051 citations · Open access

    Diabetic retinopathy (DR) is a leading cause of vision loss, and while treatments for its severe forms have improved, new therapies are needed to address the complex interplay of vascular, glial, and neuronal damage in the diabetic retina.

    Go to source

Recently added

  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 107.65 · 888 citations · Open access

    Tebentafusp significantly improved 1-year overall survival by 14% (73% vs. 59%) in previously untreated metastatic uveal melanoma patients compared to investigator's choice of therapy (pembrolizumab, ipilimumab, or dacarbazine) in a Phase 3 trial (n=378).

    Go to source

  • The Lancet Global Health Commission on Global Eye Health: vision beyond 2020

    The Lancet Global Health · 2021 · Q1 · SJR 5.00 · FWCI 171.45 · 1,543 citations · Open access

    Improving global eye health is a cost-effective strategy that unlocks human potential and directly contributes to achieving multiple Sustainable Development Goals, including poverty reduction, improved productivity, and better general health.

    Go to source

  • Glaucoma in Adults—Screening, Diagnosis, and Management

    JAMA · 2021 · Q1 · SJR 5.00 · FWCI 72.07 · 682 citations

    Glaucoma, a leading cause of irreversible blindness, can be managed by recognizing systemic risk factors and medications that predispose patients to the condition, enabling timely referral for ophthalmologic examination.

    Go to source

  • Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China

    JAMA Ophthalmology · 2020 · Q1 · SJR 2.00 · FWCI 185.86 · 1,284 citations · Open access

    Approximately one-third (31.6%) of COVID-19 patients exhibited ocular manifestations like conjunctivitis, and a small percentage (5.2%) showed SARS-CoV-2 presence in conjunctival swabs.

    Go to source

  • Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals

    Ocular Immunology and Inflammation · 2020 · Q2 · FWCI 99.50 · 716 citations

    Coronaviruses (CoVs), including SARS-CoV-2, may infect ocular tissues, with documented animal CoV infections causing conjunctivitis, uveitis, retinitis, and optic neuritis.

    Go to source

Add this field to your daily feed

Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.

Open the app

Other subfields in the same field

All fields